Addendum
Durvalumab (small cell lung cancer) - Addendum to Commission A20-87
Report documents
-
Addendum
Durvalumab (small cell lung cancer) - Addendum to Commission A20-87
Dossier assessment
Indication:
Extensive-stage small cell lung cancer (ES-SCLC)
Result of dossier assessment:
unchanged after addendum:
- Men: hint of considerable added benefit.
- Women: hint of added benefit; extent "non-quantifiable", at most "considerable".
Additional information
Federal Joint Committee (G-BA)
2021.04.01 A G-BA decision was published.
Project details
- Project no.
- A21-19
- Commission
- Commission awarded on 09.02.2021 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
Connected Projects
-
Dossier assessment
Durvalumab (small cell lung cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed